Characterization of human CD4+ T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein

被引:93
作者
ter Meulen, J
Badusche, M
Kuhnt, K
Doetze, A
Satoguina, J
Marti, T
Loeliger, C
Koulemou, K
Koivogui, L
Schmitz, H
Fleischer, B
Hoerauf, A
机构
[1] Bernhard Nocht Inst Trop Med, Dept Virol, D-20359 Hamburg, Germany
[2] Bernhard Nocht Inst Trop Med, Dept Immunol, D-20359 Hamburg, Germany
[3] Univ Hosp Eppendorf, Dept Hemotransfus, Hamburg, Germany
[4] Projet Rech Fievres Hemorragiques Guinee, Conakry, Guinea
[5] EPICTR, Grp Europeenne Expertise Epidemiol, Paris, France
关键词
D O I
10.1128/JVI.74.5.2186-2192.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
T cells must play the major role in controlling acute human Lassa virus infection, because patients recover from acute Lassa fever in the absence of a measurable neutralizing antibody response. T cells alone seem to protect animals from a lethal Lassa virus challenge, because after experimental vaccination no neutralizing antibodies are detectable. In order to study human T-cell reactivity to single Lassa virus proteins, the nucleoprotein (NP) of Lassa virus, strain Josiah, was cloned, expressed in Escherichia coli, and affinity purified, Peripheral blood mononuclear cells (PBMC) obtained from 8 of 13 healthy, Lassa virus antibody-positive individuals living in the Republic of Guinea, western Africa, were found to proliferate in response to the recombinant protein (proliferation index greater than or equal to 10). PBMC obtained from one individual with a particularly high proliferative response were used to generate 50 NP-specific T-cell clones (TCC), For six of these the epitopes were mapped with overlapping synthetic peptides derived from the sequence of the NP. These CD4(+) TCC displayed high specific proliferation and produced mainly gamma interferon upon stimulation with NP, Because variation of up to 15% in the amino acid sequences of the structural proteins of naturally occurring Lassa virus variants has been observed, the reactivity of the TCC with peptides derived from the homologous epitopes of the Nigeria strain of Lassa virus and of the eastern Africa arenavirus Mopeia was tested. With the Nigeria strain of Lassa virus the levels of homology were 100% for two of these epitopes and 85% for three of them, whereas homology with the respective Mopeia epitopes ranged from 92 to 69%, Reactivity of the TCC with peptides derived from the variable epitopes of the Nigeria strain and of Mopeia was reduced or completely abolished. This report shows for the first time that seropositive individuals from areas of endemicity have very strong memory CD4(+) T-cell responses against the NP of Lassa virus, which are partly strain specific and partly cross-reactive with other Lassa virus strains. Our findings may have important implications for the strategy of designing recombinant vaccines against this mainly T-cell controlled human arenavirus infection.
引用
收藏
页码:2186 / 2192
页数:7
相关论文
共 33 条
[1]   CONSTRUCTION OF A RECOMBINANT VACCINIA VIRUS EXPRESSING THE LASSA VIRUS GLYCOPROTEIN GENE AND PROTECTION OF GUINEA-PIGS FROM A LETHAL LASSA VIRUS-INFECTION [J].
AUPERIN, DD ;
ESPOSITO, JJ ;
LANGE, JV ;
BAUER, SP ;
KNIGHT, J ;
SASSO, DR ;
MCCORMICK, JB .
VIRUS RESEARCH, 1988, 9 (2-3) :233-248
[2]   Massive expansion of antigen-specific CD8+ T cells during an acute virus infection [J].
Butz, EA ;
Bevan, MJ .
IMMUNITY, 1998, 8 (02) :167-175
[3]  
CLEGG JCS, 1987, LANCET, V2, P186
[4]   CURRENT PROGRESS TOWARDS VACCINES FOR ARENAVIRUS-CAUSED DISEASES [J].
CLEGG, JCS .
VACCINE, 1992, 10 (02) :89-95
[5]   Production of both IFN-gamma and IL-5 by Onchocerca volvulus S1 antigen-specific CD4(+) T cells from putatively immune individuals [J].
Doetze, A ;
Erttmann, KD ;
Gallin, MY ;
Fleischer, B ;
Hoerauf, A .
INTERNATIONAL IMMUNOLOGY, 1997, 9 (05) :721-729
[6]   HLA-DR-TYPING, DQ-TYPING AND DP-TYPING USING PCR AMPLIFICATION AND IMMOBILIZED PROBES [J].
ERLICH, H ;
BUGAWAN, T ;
BEGOVICH, AB ;
SCHARF, S ;
GRIFFITH, R ;
SAIKI, R ;
HIGUCHI, R ;
WALSH, PS .
EUROPEAN JOURNAL OF IMMUNOGENETICS, 1991, 18 (1-2) :33-55
[7]   PROTECTION OF RHESUS-MONKEYS FROM FATAL LASSA FEVER BY VACCINATION WITH A RECOMBINANT VACCINIA VIRUS CONTAINING THE LASSA VIRUS GLYCOPROTEIN GENE [J].
FISHERHOCH, SP ;
MCCORMICK, JB ;
AUPERIN, D ;
BROWN, BG ;
CASTOR, M ;
PEREZ, G ;
RUO, S ;
CONATY, A ;
BRAMMER, L ;
BAUER, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (01) :317-321
[8]   EPITOPE MAPPING OF THE LASSA VIRUS NUCLEOPROTEIN USING MONOCLONAL ANTI-NUCLEOCAPSID ANTIBODIES [J].
HUFERT, FT ;
LUDKE, W ;
SCHMITZ, H .
ARCHIVES OF VIROLOGY, 1989, 106 (3-4) :201-212
[9]   SEROLOGY AND VIRULENCE DIVERSITY AMONG OLD-WORLD ARENAVIRUSES, AND THE RELEVANCE TO VACCINE DEVELOPMENT [J].
JAHRLING, PB ;
PETERS, CJ .
MEDICAL MICROBIOLOGY AND IMMUNOLOGY, 1986, 175 (2-3) :165-167
[10]   ENDEMIC LASSA FEVER IN LIBERIA .4. SELECTION OF OPTIMALLY EFFECTIVE PLASMA FOR TREATMENT BY PASSIVE-IMMUNIZATION [J].
JAHRLING, PB ;
FRAME, JD ;
RHODERICK, JB ;
MONSON, MH .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1985, 79 (03) :380-384